scholarly journals Sudden Sensorineural Hearing Loss in Human Monocytic Ehrlichiosis

2017 ◽  
Vol 96 (8) ◽  
pp. 328-342
Author(s):  
Vidur Bhalla ◽  
Brian Rodgers ◽  
James Lin
Keyword(s):  
Hearing Loss ◽  
Sensorineural Hearing Loss ◽  
Case Reports ◽  
Sudden Sensorineural Hearing Loss ◽  
Sensorineural Hearing ◽  
Older Patient ◽  
Cranial Nerve Palsies ◽  
Younger Patient ◽  
Human Monocytic Ehrlichiosis

The hallmarks of symptomatic human monocytic ehrlichiosis (HME) include fever, headache, myalgia, nausea, malaise, transaminitis, and blood cell abnormalities. Previous case reports have described isolated cranial nerve palsies in infected patients but not hearing loss. We describe the onset of sudden sensorineural hearing loss in 2 patients with HME—a 31-year-old woman and an 82-year-old woman. The older patient experienced objective and subjective improvement in her hearing after treatment with an antibiotic and steroid taper; the younger patient was lost to audiologic follow-up. Additionally, we discuss the possible mechanisms of the hearing loss in these patients.

scholarly journals Methadone Induced Sensorineural Hearing Loss

2013 ◽  
Vol 2013 ◽  
pp. 1-5 ◽  
Author(s):  
Chadi Saifan ◽  
Daniel Glass ◽  
Iskandar Barakat ◽  
Suzanne El-Sayegh
Keyword(s):  
Hearing Loss ◽  
Sensorineural Hearing Loss ◽  
Medical Literature ◽  
Case Reports ◽  
Complete Recovery ◽  
Sudden Sensorineural Hearing Loss ◽  
Sensorineural Hearing ◽  
Opiate Abuse ◽  
Methadone Overdose

Background.Sudden sensorineural hearing loss (SSHL) caused by opiate abuse or overuse has been well documented in the medical literature. Most documented case reports have involved either heroin or hydrocodone/acetaminophen. Recently, case reposts of methadone induced SSHL have been published.Case Report.We present the case of a 31-year-old man who developed SSHL after a methadone overdose induced stupor. He was subsequently restarted on methadone at his regular dose. On follow-up audiometry exams, he displayed persistent moderately severe sensorineural hearing loss bilaterally.Discussion.This case is notable because unlike all but one previously reported case, the patient—who was restated on methadone—did not make a complete recovery.Conclusion. Methadone overuse in rare cases causes SSHL.

Migraine increases the proportion of sudden sensorineural hearing loss: A longitudinal follow-up study

2019 ◽  
Vol 46 (3) ◽  
pp. 353-359 ◽  
Author(s):  
So Young Kim ◽  
Mi Kyung Kim ◽  
Jae-Sung Lim ◽  
Il Gyu Kong ◽  
Hyo Geun Choi
Keyword(s):  
Hearing Loss ◽  
Sensorineural Hearing Loss ◽  
Sudden Sensorineural Hearing Loss ◽  
Sensorineural Hearing ◽  
Follow Up Study

scholarly journals Sudden sensorineural hearing loss and vertigo associated with arterial occlusive disease: three case reports and literature review

2007 ◽  
Vol 125 (3) ◽  
pp. 191-195 ◽  
Author(s):  
Ney Penteado de Castro Junior ◽  
Clemente Isnard Ribeiro de Almeida ◽  
Carlos Alberto Herrerias de Campos
Keyword(s):  
Hearing Loss ◽  
Sensorineural Hearing Loss ◽  
Case Reports ◽  
Relevant Literature ◽  
Sudden Sensorineural Hearing Loss ◽  
Occlusive Disease ◽  
Sensorineural Hearing ◽  
Therapeutic Management ◽  
Interventional Treatment ◽  
Vascular Insufficiency

Sudden sensorineural hearing loss and vertigo (SSNHLV) has multifactorial causes, of which viral, autoimmune and vascular insufficiency are the most common. The therapeutic management for SSNHLV includes antiviral drugs, corticosteroids, vasodilators, normovolemic hemodilution therapy and hyperbaric oxygen therapy. Vertebrobasilar occlusive disease and carotid occlusive disease are seldom related to SSNHLV. Discussions concerning SSNHLV caused by occlusive vascular disease are important and necessary for both neurologists and otolaryngologists, since their therapeutic management and prognosis are very different from other causes of hearing loss and vertigo. Here, we present our experience with three cases managed with interventional treatment and conduct a review and discussion on the relevant literature. We conclude that investigation of vertebrobasilar and carotid occlusive diseases is necessary in patients over 50 years of age who present SSNHLV, mild neurological symptoms and a history of arteriosclerosis, high blood pressure or thrombosis.

scholarly journals Metformin decreases the risk of sudden sensorineural hearing loss in patients with diabetes mellitus: A 14-year follow-up study

2019 ◽  
Vol 16 (4) ◽  
pp. 324-327 ◽  
Author(s):  
Hsin-Chien Chen ◽  
Chi-Hsiang Chung ◽  
Chieh-Hua Lu ◽  
Wu-Chien Chien
Keyword(s):  
Diabetes Mellitus ◽  
Hearing Loss ◽  
Sensorineural Hearing Loss ◽  
Cox Regression ◽  
Sudden Sensorineural Hearing Loss ◽  
Sensorineural Hearing ◽  
Lower Percentage ◽  
Research Database ◽  
Patients With Diabetes

Background: The risk of sudden sensorineural hearing loss associated with metformin use in patients with diabetes mellitus has not been fully examined. Study design: It is a retrospective matched-cohort study. Subjects and methods: We examined the medical records of patients with diabetes mellitus over 18 years old in Taiwan’s National Health Insurance Research Database for the period between 1 January 2000 and 31 December 2013, to establish matched cohorts (14,109 with and 42,327 without metformin use) at a ratio of 1:3 by sex, age and index year. Results: We used a Cox regression hazard model to identify risk factors of sudden sensorineural hearing loss during 14 years of follow-up, and the results indicate that a significantly lower percentage of diabetes mellitus patients with metformin use ( p = 0.033) developed sudden sensorineural hearing loss compared with those without metformin use (0.21%, 29/14,109 vs 0.32%, 136/42,327). After adjustment for age and other variables [adjusted hazard ratio: 0.630 (95% confidence interval: 0.422–0.941, p = 0.024)], this study also demonstrated that metformin use appeared to reduce the risk of developing sudden sensorineural hearing loss. Conclusion: This study demonstrated an association between metformin use and lower incidence of sudden sensorineural hearing loss among patients with diabetes mellitus.

Sudden sensorineural hearing loss as a presentation of HIV infection

1989 ◽  
Vol 103 (11) ◽  
pp. 1071-1072 ◽  
Author(s):  
C. I. Timon ◽  
M. A. Walsh
Keyword(s):  
Cerebrospinal Fluid ◽  
Hearing Loss ◽  
Hiv Infection ◽  
Sensorineural Hearing Loss ◽  
Case Reports ◽  
Ct Scanning ◽  
Sudden Sensorineural Hearing Loss ◽  
Sensorineural Hearing ◽  
Hiv Positive ◽  
Cerebrospinal Fluid Examination

AbstractTwo case reports of HIV positive patients presenting with sudden sensorineural hearing loss are described. The importance of CT scanning and cerebrospinal fluid examination are stressed. The possible aetiology and pathology of the condition are also discussed.

Migraine is a risk factor for sudden sensorineural hearing loss: A nationwide population-based study

Cephalalgia ◽  
2012 ◽  
Vol 33 (2) ◽  
pp. 80-86 ◽  
Author(s):  
Chia-Huei Chu ◽  
Chia-Jen Liu ◽  
Jong-Ling Fuh ◽  
An-Suey Shiao ◽  
Tzeng-Ji Chen ◽  
...  
Keyword(s):  
Hearing Loss ◽  
Sensorineural Hearing Loss ◽  
Case Reports ◽  
Population Based ◽  
Cox Proportional Hazards ◽  
Sudden Sensorineural Hearing Loss ◽  
Sensorineural Hearing ◽  
Research Database ◽  
Population Based Study ◽  
Increased Risk

Background The pathophysiology of idiopathic sudden sensorineural hearing loss (SSNHL) is poorly understood. Few case reports have proposed a possible link between migraine and SSNHL. Objectives This study aimed to explore the risk of idiopathic SSNHL in patients with migraine in a nationwide, population-based cohort study. Methods We identified patients with migraine from the Taiwan National Health Insurance Research Database (NHIRD) between 2000 and 2009. Each migraine patient was matched with four randomly selected subjects without migraine for age, sex, and comorbidities. Both cohorts were followed up until the end of 2009. We compared the incidence rates of SSNHL in the two cohorts and identified the risk factors. Results A total of 10,280 migraine patients and 41,120 matched controls were enrolled with a median follow-up of five years. The migraine cohort had a greater risk of developing SSNHL than the matched cohort (81.6 vs. 45.7 per 100,000 person-years, incidence rate ratio (IRR) = 1.8; 95% confidence interval (CI) 1.22–2.61, p = 0.002). The Cox proportional hazards analysis revealed that among migraine subjects, comorbidity with hypertension was associated with a trend of developing SSNHL (hazard ratio (HR) = 1.92, 95% CI 0.97–3.79, p = 0.06). Conclusions This population-based study demonstrates that migraine is associated with an increased risk of idiopathic SSNHL, which, however, is a rare condition.

scholarly journals Long-term Follow-up Observation of Idiopathic Sudden Sensorineural Hearing Loss.

1994 ◽  
Vol 37 (4) ◽  
pp. 310-315
Author(s):  
Eiji Chida ◽  
Nobukiyo Satoh ◽  
Mitsugu Kawanami ◽  
Masaaki Kashiwamura ◽  
Satoshi Fukuda ◽  
...  
Keyword(s):  
Hearing Loss ◽  
Sensorineural Hearing Loss ◽  
Sudden Sensorineural Hearing Loss ◽  
Sensorineural Hearing ◽  
Long Term Follow Up

Long-term follow up of sudden sensorineural hearing loss patients treated with intratympanic steroids: audiological and quality of life evaluation

2014 ◽  
Vol 128 (8) ◽  
pp. 669-673 ◽  
Author(s):  
I Dallan ◽  
S Fortunato ◽  
A P Casani ◽  
E Bernardini ◽  
S Sellari-Franceschini ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Hearing Loss ◽  
Sensorineural Hearing Loss ◽  
Sudden Sensorineural Hearing Loss ◽  
Sensorineural Hearing ◽  
Glasgow Benefit Inventory ◽  
Intratympanic Steroids

AbstractObjective:To evaluate the long-term stability of intratympanic steroids and investigate the ‘real’ impact of sudden sensorineural hearing loss on patients.Method:A total of 14 patients treated with intratympanic steroids were evaluated by audiometric and vestibular examinations. The modified Glasgow Benefit Inventory was used to evaluate quality of life changes after intratympanic steroid treatment.Results:There was no significant difference between pure tone average post-intratympanic steroids and at follow up. The general Glasgow Benefit Inventory score was not significantly associated with the presence of tinnitus or dizziness, or with patient age. The change in pure tone average after intratympanic steroid treatment did not correlate with social or physical scores, but correlated strongly with the general Glasgow Benefit Inventory score (p = 0.0023). Intratympanic steroid administration led to a stable improvement in hearing. Quality of life assessment showed that patients can feel satisfaction regardless of the hearing outcome. Patients who regained a social hearing level expressed greater satisfaction than patients without serviceable hearing. Overall, quality of life improvement was not related to hearing improvement.Conclusion:Sudden sensorineural hearing loss is devastating. Considering the audiological effects alone ignores the ‘human’ perspective. Audiological success can correlate with poor quality of life outcome.

scholarly journals Comparison of Hearing Outcomes of Systemic Steroid Monotherapy and Intratympanic Steroid Combined Treatment in Idiopathic Sudden Sensorineural Hearing Loss

2021 ◽  
Vol 64 (3) ◽  
pp. 155-160
Author(s):  
Kyungil Jang ◽  
So Yun Lim ◽  
Eun-Ju Jeon ◽  
Hyun Jin Lee
Keyword(s):  
Hearing Loss ◽  
Sensorineural Hearing Loss ◽  
Pure Tone ◽  
Sudden Sensorineural Hearing Loss ◽  
Sensorineural Hearing ◽  
Systemic Steroid ◽  
Partial Recovery ◽  
Simultaneous Group ◽  
Hearing Outcomes

Background and Objectives Steroid treatment is used as a main treatment modality for sudden sensorineural hearing loss (SSNHL). Intratympanic injection of steroid (ITS) has been used and its therapeutic efficacy reported as being comparable to the systemic steroid administration (SS). This study compares the hearing outcomes of using ITS and SS simultaneously and SS alone.Subjects and Method Retrospective chart review was performed for 146 patients with SSNHL. The patients were divided into 2 groups according to the method of treatment (SS and ITS simultaneously vs. SS alone). The inclusion criteria were starting treatment within 7 days after onset, and follow up pure tone audiometry at least 4 weeks after treatment. Hearing gain for pure tone threshold of each frequency and average of 4 frequencies (500 Hz, 1000 Hz, 2000 Hz, and 4000 Hz) were compared between both groups.Results The improvement in PTA at 1-month follow-up was 27.3±20.0 dB HL in the simultaneous group and 19.1±19.5 dB HL in the SS alone group; this was not statistically significant. Complete or partial recovery at 1-month follow-up was observed in 65.3% of the simultaneous group and 69.6% of the SS alone group; this was also not significant.Conclusion There was no significant difference in hearing outcomes between the simultaneous and SS alone group. The simultaneous therapy does not appear to be superior to the SS alone therapy. Further studies using more population and longer follow-up periods are necessary.

Sign in / Sign up

Export Citation Format

Share Document